TABLE 1.
Patient demographics, characteristics, hemodynamic data and comorbidities (n=198)
| PAH (n=79) | Non-PAH (n=119) | |
|---|---|---|
| Sex, n | ||
| Female | 46 | 85 |
| Male | 33 | 34 |
| Race, n | ||
| African American | 23 | 44 |
| Caucasian | 50 | 68 |
| Age, years | 54±13 | 54±14 |
| Body mass index, kg/m2 | 30.1±6.8 | 29.8±8.9 |
| mPAP, mmHg | 40.4±12.8* | 21.7±10.0† |
| LVEF, % | 59±7 | 60±6 |
| PCWP, mmHg | 13±5 | 12±8 |
| Thermodilution CO, L/min | 5.40±1.99 | 5.57±1.99 |
| Fick CO, L/min | 5.67±2.05 | 6.05±2.48 |
| PVR, Wood units | 6.01±4.01* | 1.92±1.00 |
| Hemoglobin, g/L | 127±22.2 | 120±20 |
| Different etiologies, n (%) | ||
| Rheumatological | 22 (28) | 25 (21) |
| Obstructive sleep apnea | 11 (14) | 25 (21) |
| COPD | 20 (25) | 11 (9) |
| Sarcoidosis | 7 (9) | 16 (13) |
| Interstitial lung disease | 15 (19) | 8 (7) |
| Liver cirrhosis | 12 (15) | 9 (8) |
| Venous thromboembolic disease | 8 (10) | 5 (4) |
Data presented as mean ± SD unless otherwise indicated.
*
Seven patients had mPAP <25 mmHg due to therapy and, thus, low pulmonary vascular resistance (PVR);
†
Thirty-one patients had mPAP >25 mmHg due to pulmonary venous hypertension (WHO group 2). CO Cardiac output; COPD Chronic obstructive pulmonary disease; LVEF Left ventricular ejection fraction; mPAP Mean pulmonary artery pressure; PAH Pulmonary arterial hypertension; PCWP Pulmonary capillary wedge pressure